Table 2.
Variation in 25(OH)D levels during therapy
| Regimena | Number of Patientsb | 25(OH)D at diagnosis, ng/mL (mean) | 25(OH)D during therapy ng/mL (mean) | Number of Patients with normal 25(OH)D at diagnosis | Number of Patients with normal 25(OH)D during therapy | Fold Difference vs. baseline (median) | Fold Difference vs. baseline (95% CI) | P c |
|---|---|---|---|---|---|---|---|---|
| 0 | 16/39 | 23.0 | 19.4 | 6/16 (%) (38%) | 3/16 (19%) | 1.10 | 0.57‐1.38 | 0.3 |
| 1 | 21/35 | 25.6 | 34.8 | 6/21 (29%) | 12/21 (57%) | 1.31 | 0.99‐2.40 | 0.05 |
| 2 | 34/52 | 16.8 | 35.1 | 0/34 (0%) | 20/34 (59%) | 1.94 | 1.71‐2.22 | <0.0001 |
| 3 | 26/29 | 9.5 | 30.9 | 0/26 (0%) | 13/26 (50%) | 3.59 | 2.54‐4.23 | <0.0001 |
a
Regimen 0: no vitamin D supplementation; regimen 1: Vitamin D 25,000 IU once weekly; regimen 2: Vitamin D 25,000 IU daily for 1 week, followed by vitamin D 25,000 IU once weekly; regimen 3: Vitamin D 25,000 IU daily for 2 weeks followed by vitamin D 25,000 IU once weekly.
b
Number of patients with a second Vitamin D level during therapy/total number of patients in the group of regimen of supplementation.
c
Comparison of 25(OH)D levels at start and during therapy using paired t‐test. Significant p‐values (<0.05) are indicated in bold.